Kornimate/medical-research-clean huggingface dataset:
cracking the code of crying babies: how familiarity changes the interpretation of cries

Conditions: Magnetic Resonance Imaging; Neuronal Activity

Summary: understanding babies' signals is essential to meet their needs. recent works suggest that crying provides useful information, not only allowing parents to recognize their baby among others (static information), but also to distinguish between mild discomfort and pain cries (dynamic information). the perception of this information by adults involves a "parental" brain network including brain areas involved in empathy, attention, emotional regulation, motor as well as regions of the limbic system or associated with the reward network.

this network is involved when listening to cries of familiar babies, or pain cries. how do we become specialist of a baby's cries? to date, no functional imaging study has examined the specific brain activations when listening to the cries of a familiar baby in different situations, particularly painful ones.

Eligibility criteria:
inclusion criteria for all volunteers: * affiliated or entitled to a social security plan * right-handed by the edinburgh laterality test * having given free, informed and written consent to participate in the study * having given their consent for the communication of the mri results to their attending physician group with parental experience caring for infants : * men or women between 18 and 50 years old * parent of a child under 2 years old group with professional experience in caring for infants * women between 18 and 50 years old * without dependent children under 2 years of age * people in daily contact with infants in the professional circle (e.g. nurses, pediatricians, midwives, maternity nurses, etc) exclusion criteria * pregnant women, parturient, nursing mothers or parents * persons deprived of liberty, hospitalized without consent, hospitalized for purposes other than research * minors * adults under legal protection (guardianship) or unable to express their consent * subjects with contraindications to the mri examination: use of a pacemaker or an insulin pump, wearing a metallic prothesis, an intracerebral clip or a piercing, claustrophobia, * taking medication for less than 12 hours, * neurological, psychiatric or auditory history or deficits. * anxiety and/or depressive disorders

Keywords: baby cries pain brain responses fmri familiarity
the association with peptic ulcer disease and hepatic vein pressure gradient

Conditions: Cirrhosis; Chronic Liver Disease

Summary: the aim of this study is to assess the role of portal hypertension of peptic ulcer disease in liver cirrhosis and chronic hepatitis.

retrospective case-control study * investigators will analyze the medical records of hepatic vein pressure gradient (hvpg) and esophagogastroduodenoscopy (egd) cases who had liver cirrhosis (lc) or chronic hepatitis in a single tertiary hospital (chuncheon sacred heart hospital, korea) within 2008\~2012. * portal hypertension is assessed using hvpg measurement via transjugular approach. * peptic ulcer is evaluated through egd within 3 months of hvpg measurement * the association of peptic ulcer with lc, chronic hepatitis and total population (lc or chronic hepatitis) will be assessed by univariate and multivariate analysis * there is no specific time frame, because this study is retrospective observational study, however egd data is enrolled if it was done within 3 month from hvpg measurement.

Eligibility criteria:
inclusion criteria: * the patients who underwent hepatic vein pressure gradient (hvpg) measurement and esophagogastroduodenoscopy (egd) and also had lc or chronic hepatitis exclusion criteria: * the patients who have missing or incomplete hvpg or egd data * the patients who underwent gastrectomy * the patients who have systemic malignancy

Keywords: peptic ulcer liver cirrhosis portal hypertension
the effect of dry needling treatment combined with physical therapy in patients with cervical spondylosis

Conditions: Dry Needling; Cervical Spondylosis; Physical Therapy

Summary: in this study, it was aimed to determine whether dry needling treatment applied to the trigger points in the trapezius muscle in patients with chronic neck pain due to cervical spondylosis makes an additional contribution to the treatment results of the physical therapy and rehabilitation program.

among the evaluated patients, the patients meeting the inclusion and exclusion criteria will be randomized into 2 groups using the random numbers table. while physical therapy and rehabilitation program will be applied to one group, dry needling treatment will be applied to the trigger points in the upper trapezius region with the same program to the other group. patients will be evaluated before treatment (day 0) and at the end of treatment (day 21). the randomization and evaluation of the patients will be done by gül tuğba bulut, while the injection of the patients will be done by alper mengi. gender, age, education level, occupation, neck pain duration, body mass index of the patients included in the study will be recorded. the patients will be evaluated in terms of pain intensity, number of active trigger points in the upper trapezius muscle, functional status, quality of life, anxiety and depression at before (day 0) and after treatment (day 21).

Eligibility criteria:
inclusion criteria: * having neck pain for at least 3 months * restriction of neck movements and/or pain during movement * tenderness in neck paravertebral muscles and neural foramen with compression * detection of narrowing of intervertebral disc spaces, subchondral sclerosis, osteophyte on cervical radiograph * active trigger point in the upper trapezius muscle during the examination. exclusion criteria: * having motor, sensory or reflex abnormalities due to spinal root compression * whiplash injuries * cervical spinal stenosis * having undergone cervical vertebra surgery * history of interventional procedure on the cervical region in the last 6 months * central or peripheral nervous system disorders * spondylolisthesis * inflammatory neck pain * history of infectious, chronic inflammatory disease, malignancy * not being cooperative * having open wounds, infections or sensory defects on the skin where the application will be made * fibromyalgia * advanced osteoporosis or osteomalacia * active psychiatric illness.
safety and efficacy of the cryocor™ cardiac cryoablation system for the treatment of atrial flutter

Conditions: Atrial Flutter

Summary: the purpose of this study is to evaluate the safety and efficacy of right atrial intra-cardiac lesions created by transvenous catheter cryoablation in patients with atrial flutter.

catheter ablation of arrhythmias has become an accepted alternative to pharmacologic therapy. cryoablation is a newer alternative to radiofrequency ablations. this study expands the prior pilot experience with the cryocor™ cardiac cryoablation system to a larger cohort of patients with atrial flutter.

Eligibility criteria:
inclusion criteria: * symptomatic atrial flutter exclusion criteria: * prior ablation * contraindication to intervention * poor general health

Keywords: atrial flutter cryoablation
effect of desipramine on genioglossus muscle activity in healthy adults study a

Conditions: Sleep Apnea, Obstructive

Summary: obstructive sleep apnea (osa) is common and has major health implications but treatment options are limited. osa patients show a marked reduction in upper airway (ua) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of ua compared to normal participants. until recently, the search for medicines to activate pharyngeal muscles in sleeping humans has been discouraging. however, exciting new animal research has shown that drugs with noradrenergic and antimuscarinic effects can restore pharyngeal muscle activity to waking levels. in this protocol the investigators will test the effect of desipramine (a tricyclic antidepressant with strong noradrenergic and antimuscarinic effects) on genioglossus muscle activity (emg gg) during sleep in healthy control participants.

two overnight sleep studies, a placebo night and a drug night, will be performed approximately one week apart in random order. the placebo or drug will be administered 2 hours before lights out. at least 15 minutes of quiet wakefulness will be recorded to quantify the participant's awake emg gg activity. participants will then sleep in the lateral position to minimize pharyngeal resistance similar to previous studies of this kind. the same will be done for stable non-rapid eye movement (nrem) and rapid eye movement (rem) sleep (free of arousals and other artifacts). both nrem and rem sleep will be analyzed, recognizing that rem is less frequent on these drugs. during the second part of the night, the participants will be connected to a modified continuous positive airway pressure (cpap) machine (pcrit3000, respironics) which can provide a wide range of pressures between 20 and -20 cm h2o in order to modify upper airway pressure and measure change in emg gg as a function of epiglottic pressure (muscle responsiveness).

Eligibility criteria:
inclusion criteria: * healthy control subjects exclusion criteria: * cardiovascular disease other than well controlled hypertension * depression
capecitabine and oxaliplatin in patients with advanced or metastatic pancreatic adenocarcinoma

Conditions: Pancreatic Cancer

Summary: there are limited treatment options available for patients with advanced pancreatic ductal adenocarcinoma (pdac). the purpose of this study is to determine the effectiveness and safety of the drugs capecitabine and oxaliplatin in patients who have been diagnosed with advanced and metastatic pdac treated in the first and second lines.

objectives: primary * to determine the response rate to capecitabine and oxaliplatin in patients with locally advanced or metastatic pancreatic adenocarcinoma secondary * to determine safety * to determine overall survival * to determine time to progression

Eligibility criteria:
inclusion criteria: * 18 years of age or older * at most one prior chemotherapy regimen for unresectable or metastatic disease. any adjuvant chemotherapy must have been completed more than 12 months prior to beginning protocol therapy * histologically or cytologically confirmed adenocarcinoma of the pancreas * at least one measurable lesion according to recist criteria that has not been irradiated * adequate laboratory parameters as outlined in protocol * anticoagulation with coumadin is permitted, but pt/inr must be monitored closely, given the drug-drug interaction between coumadin and capecitabine * negative serum pregnancy test within 14 days prior to registration exclusion criteria: * pregnant or lactating women * life expectancy \< 3 months * serious, uncontrolled, concurrent infection(s) * any prior oxaliplatin or fluoropyrimidine therapy * more than one prior chemotherapy regimen for unresectable or metastatic disease * prior unanticipated severe reaction to fluoropyrimidine therapy, or known sensitivity to 5-fluorouracil or platinum compounds * any active second malignancy * clinically significant cardiac disease or myocardial infarction within the last 12 months * evidence of cns metastases or history of uncontrolled seizures, central nervous system disorders or psychiatric disability * other serious uncontrolled medical conditions * major surgery within 4 weeks of the start of study treatment, without complete recovery * lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome * known, existing uncontrolled coagulopathy

Keywords: capecitabine oxaliplatin
assessment of zegerid on esophageal ph in patients with barrett's esophagus

Conditions: Barrett Esophagus; Gastroesophageal Reflux

Summary: the purpose of this research study is to assess how safe, effective (how well it works), and tolerable (to put up with) the drug zegerid is in reducing reflux episodes in patients who have both gastroesophageal reflux disease (gerd) and barrett's esophagus. zegerid has been approved by the us food and drug administration (fda) for the treatment of gerd. the investigators hope to learn the effectiveness of zegerid for reducing the amount of acid reflux patients are experiencing in the esophagus (swallowing pipe).

the following procedures will be performed at the screening visit: * obtain informed consent. * obtain information about your age and gender. * evaluate whether you qualify for the study. * document prior negative testing for h. pylori infection (a bacterial infection in the stomach that can cause ulcers) including the date of testing. * make sure that you have not used any investigational medications or participated in a clinical trial in the 30 days prior to the screening visit. * obtain medical history. * record medication history (including concomitant medications). * obtain vital signs. * conduct a physical examination. * if a bravo ph study has not been done within 8 weeks, instruct the patient to discontinue their medication for gerd during the 7-10 day washout period. * instruct the patient to discontinue the use of all prohibited medications during the applicable time intervals and not to start any new concomitant medications during the trial. * distribute gelusil tablets to be used as "rescue medication"; instruct the patient that no more than 6 gelusil tablets per day or 21 tablets over any 7-day interval will be allowed. * schedule the patient to return for the qualification visit, or for ph monitoring and the qualification visit. only patients with abnormal ph monitoring will be able to enter the treatment period. procedures that will occur during the treatment period: * you will receive zegerid 1 hour before breakfast and at bedtime for at least 14 days and no longer than 28 days * at the end of the zegerid treatment period, you will undergo 48-hour bravo ph monitoring on zegerid therapy for two days. you will complete a symptom survey and quality of life survey after the completion of the ph study.

Eligibility criteria:
inclusion criteria: * inclusion criteria include adult men and women (aged \<=18 years) with previously established, biopsy-proven diagnosis of be (any length intestinal metaplasia without dysplasia or adenocarcinoma) exclusion criteria: * exclusion criteria include a history of esophageal, gastric, or duodenal surgery (including antireflux surgery or endoscopic antireflux procedures), except for simple ulcer closure * zollinger-ellison syndrome * endoscopic evidence or suspicion of a pathologic or infiltrative process in the stomach * positive for h. pylori.
effect of vancomycin after catheter replacement

Conditions: Central Line-associated Bloodstream Infection (CLABSI); Catheter-related Bloodstream Infection

Summary: randomized controlled trial of the effect of a single-dose intravenous vancomycin after catheter replacement for suspected central line-associated bloodstream infection on resolution of infection in critically ill patients.

patients on the local intensive care unit with suspicion of central line-associated bloodstream infection will be randomized to standard of care consisting of catheter replacement and blood and catheter tip cultures and to standard of care plus a single-dose vancomycin. the effect of the intervention on resolution of humoral inflammation and negativity of blood cultures will be assessed after 48 and 96 hours.

Eligibility criteria:
inclusion criteria: suspected central line-associated bloodstram infection defined as: * catheterization with a non-tunneled cvc and * clinical signs of local catheter infection or any increase in humoral inflammatory markers (pct, crp, wbc) or elevated body temperature ≥ 38.3°c not otherwise explained. baseline crp at screening ≥ 100 mg/l exclusion criteria: * known positive blood cultures at the time of randomization * high risk situation warranting immediate empiric antibiotic therapy: * endovascular implant (prosthetic valve, pacemaker, vascular graft) * high-risk for endocarditis warranting endocarditis-prophylaxis * septic shock * catheter replacement not feasible or no further indication for central venous catheterization * known hypersensitivity to vancomycin or any component of the formulation. * administration of vancomycin, teicoplanin, daptomycin or linezolid \<48 hours before enrolment. * enrolment in another clinical study * pregnancy

Keywords: central line-associated bloodstream infection catheter-related bloodstream infection vancomycin critical care bloodstream infection
single cell acute leukemia analysis

Conditions: Acute Myeloid Leucemia

Summary: numerous chemotherapy and immunotherapy resistance genes have been identified in cancers in general and acute myeloid leukemia in particular. as a preliminary to this study, the investigators hypothesized the co-expression of these genes in the same cell as a major factor in relapse. this hypothesis was supported in vitro by the study of the evolution of these co-expressions after incubation with chemotherapy drugs. the current study aims to verify this hypothesis by studying the expression of these genes in single-cell samples from relapsed acute myeloid leukemia patients.


Eligibility criteria:
inclusion criteria: * adult patient * patient who has received information about the study and has not expressed opposition, * patients who are beneficiaries of a social security plan, * patient with relapsed or refractory acute myeloid leukemia, whatever the previous treatment, the therapeutic line and the time between the previous treatment and the relapse. exclusion criteria: * persons who do not understand the french language if there is no translator available to translate for them. * absence of circulating blastosis.
a clinical trial to evaluate the safety and efficacy of enjuvia 0.3 mg for the treatment of vulvovaginal atrophy

Conditions: Menopause

Summary: this is a two-arm, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy of enjuvia 0.3 mg tablets for the treatment of moderate to severe symptoms of vulvovaginal atrophy in postmenopausal women with or without a hysterectomy and/or oophorectomy.

the study will include a screening period up to 4 weeks and a 12-week treatment period. the overall study duration for participants will be approximately 16 weeks. study participants will undergo physical and gynecological exams, and blood tests for clinical laboratory assessments. all patients with a uterus will undergo transvaginal ultrasound.

Eligibility criteria:
inclusion criteria: * naturally or surgically postmenopausal * moderate or severe symptoms of vaginal atrophy (ie, dryness, itching, pain, uncomfortable intercourse) exclusion criteria: * known sensitivity or contraindication to estrogens or progestins * history or current diagnosis of endometrial hyperplasia * recent history of vaginal bleeding of unknown cause * recent history or diagnosis of endometriosis * any contraindication to estrogen therapy

Keywords: vaginal atrophy vaginal dryness vaginal itching vaginal pain dyspareunia
lycopene in preventing of prostate cancer

Conditions: Prostate Cancer

Summary: rationale: chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. the use of lycopene may be an effective way to prevent prostate cancer. purpose: phase i trial to study the effectiveness of lycopene in preventing prostate cancer.

objectives: * determine any dose limiting toxicities and the maximum tolerated dose of lycopene administered orally as a food based delivery system in healthy male subjects 18-45 years of age for the chemoprevention of prostate cancer. * determine the pharmacokinetics of this regimen in this population. * determine the dose range of this regimen to be used in the 3 month multiple dose study, based on the toxicity, pharmacokinetics and feasibility resulting from the present study in this population. outline: this is a dose-escalation study. patients receive a single dose of oral lycopene in a mixture of tomato paste, water, and olive oil over 15 minutes on day 1. patients are asked to maintain a diet that contains negligible carotinoid for 28 days. cohorts of 5 patients receive escalating doses of lycopene until the maximum tolerated dose (mtd) is determined. the mtd is defined as the dose preceding that at which 2 of 5 patients experience dose limiting toxicities. patients are followed weekly for 4 weeks. projected accrual: a total of 5-25 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * normal healthy males judged to be in good medical condition based on history and physical exam confirming the absence of chronic medical conditions * baseline serum lycopene less than 600 nm patient characteristics: age: * 18 to 45 performance status: * karnofsky 100% life expectancy: * not specified hematopoietic: * hematologic function normal hepatic: * liver function normal * no hepatic disease renal: * kidney function normal * no renal disease cardiovascular: * no hypertension requiring medication * no cardiovascular disease * normal ekg other: * no evidence of a psychiatric disorder * must be within 15% of ideal body weight based on standard weight tables * no history of smoking within the past 3 months * at least 72 hours since prior alcohol consumption and no history of alcohol abuse * no history of gastrointestinal malabsorption or any other condition that could affect drug absorption * no allergy to tomato based products * no active malignancy at any site * no illness that would pose a threat or additional risk (e.g., thyroid disease, diabetes mellitus) prior concurrent therapy: biologic therapy: * not specified chemotherapy: * not specified endocrine therapy: * not specified radiotherapy: * not specified surgery: * not specified other: * at least 14 days since prior prescription drugs * no concurrent regular prescription medications * at least 30 days since other prior experimental drugs * no concurrent participation in any other experimental trial

Keywords: prostate cancer
central and peripheral blood pressure in treatment of obstructive sleep apnea.

Conditions: Hypertension; Obstructive Sleep Apnea

Summary: the purpose of this study is to examine the effect on blood pressure of 3 months of treatment with continuous positive airway pressure (cpap) in patients with obstructive sleep apnea (osa). hypothesis: 1. central 24-h blood pressure (bp) monitoring hedges day fluctuations in blood pressure more accurately than peripheral 24-h bp monitoring, because the measurement is painless and does not interfere with the patient / subject's activities during the daytime or nighttime sleep. 2. blood pressure is elevated in patients with osa and falls during treatment with cpap. 3. the renal treatment of salt and water is abnormal in osa, improved during treatment with cpap. 4. quality of life improves during treatment with cpap

approximately 20 patients with hypertension and moderate to severe osa are treated with cpap 3 months to examine the treatment effect on blood pressure throughout the day, but especially nocturnal, renal treatment of salt and water, and quality of life. before and after 3 months of cpap treatment is made central and peripheral 24-h ambulatory blood pressure monitoring, 24-h urine collection and blood samples.

Eligibility criteria:
inclusion criteria: * chronic kidney disease (ckd stage i and ii), egfr 60-90 ml/min/1.73 m2 or egfr\> 90 ml/min/1.73 m2 and proteinuria or other signs of kidney damage. * obstructive sleep apnea, apnea hypopnea index (ahi) \> 15 (moderate to severe) * both men and women * 55-70 years * signed consent form exclusion criteria: * lack of desire to participate * malignant disease * abuse of drugs or alcohol * pregnant and breastfeeding * incompensated heart failure * atrial fibrillation * liver disease (alanine aminotransferase (alt) \> 200) * severe chronic obstructive pulmonary disease (forced expiratory volume in 1 second \<50% predicted) * blood pressure difference between the right and left arm\> 10/10 mmhg

Keywords: continuous airway pressure hypertension obstructive sleep apnea